Diabetes Medicines In DPP-4 Inhibitor Class Might Not Increase Risk Of Inflammatory Bowel Disease (IBD) 

But New Medical Study Finds That Januvia, Onglyza, Other Drugs In Class Significantly Increase Risk Of Crohn's Disease (CD)   (Posted by Tom Lamb at DrugInjuryWatch.com)   Back in March 2018 we wrote this report, "Januvia, Onglyza, And Certain Other Diabetes Drugs Linked To Inflammatory Bowel Disease (IBD)", which was about a study published by The BMJ medical journal about the use of dipeptidyl peptidase-4 (DPP-4) inhibitors for treatment of type 2 diabetes being associated with increased risk for IBD. Now, about a year later, the medical journal Annals of Pharmacotherapy posted an article, "Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis", which indicates that DPP-4 inhibitors do not appear to increase the risk of developing IBD after all — or at least for the time being. The following diabetes medicines are in the DPP-4 inhibitor class of drugs: Januvia (sitagliptin)Janumet (sitagliptin / metformin…

Read more detail on Recent Health Care Law posts –

This entry was posted in Health Law and tagged , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply